Telo Genomics Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TDSGF research report →
Companywww.telodx.com
Telo Genomics Corp. , a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases.
- CEO
- John Allen Farlinger
- IPO
- 2021
- Employees
- 8
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $3.11M
- P/E
- -2.11
- P/S
- 0.00
- P/B
- -9.98
- EV/EBITDA
- -2.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -990.56%
- ROIC
- 663.94%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,718,753 · -0.21%
- EPS
- $-0.02 · 40.00%
- Op Income
- $-2,702,382
- FCF YoY
- 5.37%
Performance & Tape
- 52W High
- $0.09
- 52W Low
- $0.03
- 50D MA
- $0.04
- 200D MA
- $0.04
- Beta
- 0.12
- Avg Volume
- 5.03K
Get TickerSpark's AI analysis on TDSGF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TDSGF Coverage
We haven't published any research on TDSGF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TDSGF Report →